UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 11, 2015
COLUCID PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-37358 | 20-3419541 | ||
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
222 Third Street, Cambridge, Massachusetts 02142
(Address of principal executive offices) (Zip Code)
(857) 285-6495
(Registrant’s telephone number, include area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 11, 2015, CoLucid Pharmaceuticals, Inc. (the “Company”) agreed with Nadia Rupniak, its Head, Research, that, effective December 31, 2015, her employment with the Company would terminate. The Company and Dr. Rupniak are discussing a potential consulting arrangement to take effect following her termination of employment.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| COLUCID PHARMACEUTICALS, INC. | ||||||||
| Date: December 17, 2015 | By: | /s/ Matthew Dallas | ||||||
| Matthew Dallas Chief Financial Officer | ||||||||